Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC

NCT07024680 · clinicaltrials.gov ↗

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Papillary Renal Cell Carcinoma

Interventions

OTHER: Observational, None intervention

Sponsor

AstraZeneca